合成生物学领域的领先企业Twist Bioscience Corp（股票代码：TWST）近日宣布，公司预计将在2026财年第四季度实现调整后税息折旧及摊销前利润（EBITDA）的盈亏平衡点。这一里程碑式的财务目标标志着公司向可持续盈利模式迈出关键一步。
通过持续优化运营效率和扩大高利润率产品线，Twist Bioscience正稳步推进其战略规划。公司高管表示，这一预期基于当前业务增长趋势和技术平台商业化进程的综合评估。
合成生物学领域的领先企业Twist Bioscience Corp（股票代码：TWST）近日宣布，公司预计将在2026财年第四季度实现调整后税息折旧及摊销前利润（EBITDA）的盈亏平衡点。这一里程碑式的财务目标标志着公司向可持续盈利模式迈出关键一步。
通过持续优化运营效率和扩大高利润率产品线，Twist Bioscience正稳步推进其战略规划。公司高管表示，这一预期基于当前业务增长趋势和技术平台商业化进程的综合评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.